Photo by Mostafa Agami on Unsplash.
By David L. Carpenter, BSN, RN.
If you’re thinking about switching GLP-1 medications, you may feel hopeful, frustrated, or worried about starting over. Perhaps insurance changed, refills became difficult, or side effects are getting in the way. You deserve a clear plan—not pressure to figure it out yourself.
A change in treatment is not a personal failure. This guide covers prescribed weight-management treatments such as semaglutide (Wegovy) and tirzepatide (Zepbound), a dual GIP/GLP-1 medicine. The useful question is what fits your health needs now. Medication choice should account for benefits, side effects, other medicines, medical history, and cost. NIDDK medication overview
Key takeaways
- Get a written plan from your prescriber before changing products. Ask your pharmacist to review it with you.
- Record your previous medicine, dose, and the date and time you last took it.
- Do not use an online dose-conversion chart to manage a switch yourself.
- Ask about refills, side effects, other medicines, and follow-up—not just the new prescription.
- Follow your Medication Guide’s emergency instructions if serious symptoms occur.
Why people consider a change
You might want to discuss cost, coverage, supply problems, troublesome symptoms, or results that do not match your goals. Tell your clinician which concern matters most. “I cannot reliably fill this prescription” deserves attention just as much as “I feel too sick to eat comfortably.”
No medication is the best choice for everyone. Ask what improvement your prescriber hopes to see and how you will judge whether the change is helping. Tell them how you’re managing day to day: appetite, energy, and side effects. NIDDK medication overview
Questions to ask before switching GLP-1 medications
Bring your medication list and a photo of the current package. Include prescriptions, nonprescription medicines, vitamins, and supplements. Ask:
- Why are we changing treatment, and what are the alternatives?
- What exact product, formulation, and device am I receiving?
- What starting dose have you prescribed, and when should I take it relative to my last dose?
- How will you decide when to increase the dose?
- What should I do if the new medicine is unavailable when the plan says to start?
- Which symptoms should prompt a call? Who handles questions after hours?
- What should I monitor, and when is my follow-up?
Ask the pharmacist to explain the package directions and demonstrate an unfamiliar device. If the prescription, written plan, and verbal instructions differ, get them clarified before taking the medicine. It is reasonable to say, “Please write that down so I do not mix up the old and new instructions.”
A switch is not a do-it-yourself dose conversion
Your prescriber sets the plan. A dose number from one product is not a personal instruction for another. Do not independently switch, skip, stop, restart, or combine medicines to make the transition work.
Do not combine GLP-1-based medicines on your own. Wegovy and Zepbound labels state that use with another GLP-1 receptor agonist, or another product containing the same active ingredient, is not recommended. If instructions appear to overlap, have the prescriber and pharmacist resolve that before use. Wegovy prescribing information; Zepbound prescribing information
Keep a record of the last dose of the previous medication. Ask the pharmacy to flag discontinued prescriptions so an old automatic refill does not cause confusion.
After a gap, the restart plan may be different
Do not assume your previous dose remains the right place to resume. For Wegovy injections, current prescribing information directs restarting dose escalation at a lower dose after specified consecutive missed doses to reduce gastrointestinal side effects. That is a product-specific instruction, not a universal restart rule. Wegovy prescribing information, section 2.4
Tell your prescriber exactly how long you have been without treatment and what symptoms you previously experienced. Ask whether you need a fresh escalation plan. Stomach symptoms may occur again during treatment initiation or increases; having tolerated an earlier regimen does not settle the new plan. Joint GLP-1 nutrition advisory
Pills and injections have different instructions
An injection-to-pill or pill-to-injection change needs its own plan. Instructions about food, water, timing, other medicines, and storage may differ between oral products. Do not carry instructions from one product to another. Wegovy’s labeling, for example, gives separate administration instructions for tablets and injections. Wegovy prescribing information
Ask your pharmacist to walk through an ordinary day with you: breakfast, other medicines, work, and bedtime. Keep the current Medication Guide and storage instructions accessible.
Check coverage and supply before the handoff
Before switching GLP-1 medications, call your insurer about the exact product and formulation, not just whether it covers “GLP-1s.” Ask whether prior authorization is required, what your prescriber must submit, and what your expected out-of-pocket cost will be. Ask how long an authorization lasts and what is required at renewal. Coverage varies by plan. NIDDK insurance guidance
Ask the pharmacy about availability, ordering time, and required supplies. Tell the prescriber promptly if the proposed plan is unaffordable or the medicine cannot be obtained. Request a contingency plan instead of improvising with leftover medication.
Keep a brief record of calls, names, and next steps. A clear message—“The pharmacy cannot fill the prescribed product; what should I do?”—helps the office address the actual problem.
Compounded products need particular care
Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before marketing. Compounding can meet certain medical needs, but it is not the same as receiving an FDA-approved product. FDA concerns about unapproved GLP-1 drugs
FDA has reported dosing errors with compounded injectable semaglutide, including cases requiring hospitalization. Concentrations and containers can differ, and confusion between measurement units has contributed to errors. FDA dosing-error alert
If your previous treatment was compounded, show the prescriber and pharmacist its actual label and directions. HCW’s compounded GLP-1 recall guide explains how to check your medication. Do not transfer a syringe marking or remembered amount to a new product.
Review your other medicines
If you use insulin or a sulfonylurea, ask about low blood sugar, glucose monitoring, and whether your clinician needs to adjust treatment. Do not change those medicines yourself. Zepbound labeling warns of increased hypoglycemia risk with these medicines. Zepbound prescribing information, section 7.1
Some GLP-1-based treatments can affect oral medicine absorption by slowing stomach emptying. Zepbound’s label calls for caution and, for certain oral medicines, monitoring. It also has specific precautions for oral hormonal contraception when treatment starts or doses increase. Ask for a contraception plan if relevant; have your prescriber explain the method and duration required by the current label. Zepbound prescribing information, sections 7.2 and 8.3
Make daily routines manageable
Smaller, regular meals may be easier to tolerate than large meals. Include protein foods you can manage, such as eggs, yogurt, beans, or fish, while following any dietary restrictions. Ask for individualized nutrition help if eating enough becomes difficult. Joint GLP-1 nutrition advisory
Drink regularly within your medical plan; do not override fluid restrictions. Ask about constipation early rather than waiting until it is severe. Joint GLP-1 nutrition advisory
Keep a simple log of doses, nausea, vomiting, bowel changes, food and fluid intake, and any requested glucose readings. Share changes with your care team. The goal is useful information, not perfect tracking.
Symptoms that need prompt attention
Severe abdominal pain that does not go away: Wegovy and Zepbound Medication Guides instruct patients to stop the medicine and contact a healthcare provider immediately. Pain may extend toward the back and occur with or without vomiting. Wegovy Medication Guide; Zepbound Medication Guide
Persistent vomiting: The Zepbound Medication Guide instructs patients to tell their healthcare provider right away about nausea, vomiting, or diarrhea that does not go away. It warns that fluid loss can lead to kidney problems. Zepbound Medication Guide
As a practical precaution, if you cannot keep fluids down, contact your care team promptly or seek urgent care rather than waiting for a routine appointment.
Possible serious allergic reaction: Stop the medicine and get immediate medical help for symptoms such as facial or throat swelling, trouble breathing or swallowing, or fainting. Call emergency services for breathing difficulty, throat swelling, or collapse. Zepbound Medication Guide
These emergency instructions are different from changing treatment on your own for convenience. Read your exact product’s Medication Guide; this is not a complete list of warnings.
Before-you-switch checklist
- Exact product, formulation, device, and pharmacy confirmed.
- Previous dose and last-dose date recorded.
- Written dosing and transition plan understood.
- Coverage, supply, and possible delays discussed.
- Other medicines and relevant medical history reviewed.
- Procedure team informed of current treatment if surgery or a procedure is planned. Zepbound Medication Guide
- Current Medication Guide and storage instructions reviewed.
- Side-effect, emergency, after-hours contact, and follow-up plans available.
Frequently asked questions
Will I have to start over?
Ask your prescriber. Previous treatment and any gap need consideration; do not assume you can carry over your old dose. The restart instructions above illustrate why the exact product matters.
Can I use leftover medicine while waiting?
Do not create your own bridge plan. Tell the prescriber what you have and when the new prescription will be available. Ask for explicit instructions.
What if the new plan feels too complicated?
Request a one-page schedule written for you, then repeat it back to the pharmacist. Ask whom to contact if something changes. You do not need to manage uncertainty alone.
This article provides general education, not individualized medical advice. Your prescriber and pharmacist should guide medication changes and address your personal health needs.
References
- NIDDK. Prescription Medications to Treat Overweight & Obesity. General treatment selection and coverage guidance.
- Novo Nordisk. Wegovy prescribing information and Medication Guide. Revised June 2026. Product limitations; administration; missed doses; safety instructions.
- Eli Lilly. Zepbound prescribing information. Revised August 2026. Product limitations and drug interactions.
- Eli Lilly. Zepbound Medication Guide. Revised August 2026. Symptoms requiring prompt action.
- FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
- FDA. Dosing Errors Associated with Compounded Injectable Semaglutide Products.
- Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory. American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. American Journal of Lifestyle Medicine, 2025. doi:10.1177/15598276251344827.









